# KPV: Research Overview — Sovereign Peptides > A literature summary of KPV (Lys-Pro-Val), the anti-inflammatory tail of alpha-MSH, studied chiefly in models of gut inflammation. Covers PepT1 uptake, NF-kB suppression and the preclinical-only evidence base. A three-amino-acid piece of alpha-MSH that keeps the parent hormone's anti-inflammatory action while dropping its pigment effect — studied most in inflamed gut. ## The short version KPV is one of the smallest peptides you will meet — just three amino acids: lysine, proline, valine. It is the tail end (the last three residues) of a hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. The interesting part is that this little tail keeps the parent hormone's *anti-inflammatory* power but leaves behind its skin-darkening (pigment) effect [22]. Unlike the other three peptides here, KPV is not really about building tissue — it is about *calming* the inflammation that can stall healing, and most of its research is in animal models of inflamed gut (colitis) [20]. Be clear-eyed about the stage of evidence: there are no published human clinical trials of KPV at all. It is sold for laboratory research only, it is not an approved drug or supplement, and this page lists no human dose. ## What it is KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (Lys-Pro-Val), corresponding to residues 11-13 — the C-terminal, or tail, sequence — of alpha-MSH. Because it is derived from a melanocortin hormone you will also see it written as alpha-MSH(11-13). Its defining feature in the literature is that it preserves anti-inflammatory activity *without* the pigmentary (melanogenic) action of the full hormone, which is why researchers describe it as an anti-inflammatory alternative to alpha-MSH rather than a tanning agent [22]. It is a research peptide with no approved drug or supplement status in any major jurisdiction. ## How it works KPV dampens inflammation primarily by suppressing two master inflammatory switches inside cells: the transcription factor *NF-kB* and the *MAP-kinase* signaling pathways. Quieting those reduces the output of pro-inflammatory messengers (cytokines such as IL-1beta and TNF-alpha) [20]. There is also a neat delivery twist in the gut. KPV is small enough to be carried directly into intestinal lining cells by a di/tripeptide transporter called *PepT1* (gene SLC15A1) — and PepT1 is upregulated precisely in inflamed intestinal tissue, so the transport route is most active where the inflammation is [20]. At nanomolar concentrations, KPV taken up this way reduced NF-kB and MAPK activation and lowered cytokine secretion in both epithelial and immune cells [20]. Notably, its anti-inflammatory effect was retained even in mice lacking the MC1R receptor, indicating an MC1R-*independent* mechanism — it is not simply acting through the classic melanocortin receptor [21]. ## What the research shows *Mechanism in cells and mice.* The foundational study showed PepT1-mediated KPV uptake into human intestinal epithelial cell lines and Jurkat T cells, with nanomolar KPV inhibiting NF-kB and MAP-kinase signaling and reducing pro-inflammatory cytokine secretion; orally administered KPV reduced the severity of two chemically induced colitis models (DSS and TNBS) in mice [20]. *Colitis recovery.* In murine colitis, the melanocortin-derived tripeptide KPV produced earlier recovery, stronger regain of body weight, reduced inflammatory infiltrate and lower myeloperoxidase activity (a marker of inflammatory cell activity); the effect persisted in MC1R-deficient mice, confirming an MC1R-independent route [21]. *Targeted delivery.* Because free KPV is fragile, much recent work is formulation science. Orally administered hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue and reduced colitis severity more effectively than non-targeted formulations, downregulating TNF-alpha and accelerating mucosal healing [19]. A 2024 PepT1-targeted nanodrug co-assembling KPV with an immunosuppressant improved both acute and chronic colitis in mice, restoring tight-junction proteins and lowering inflammatory cytokines beyond either agent alone [18]. *Breadth review.* A comprehensive review of alpha-MSH and related tripeptides describes KPV and relatives showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic and organ-injury models, delineating KPV specifically as the anti-inflammatory option that lacks pigmentary action [22]. ## Reported effects, cautions & safety The cautions for KPV are dominated by one fact — the evidence is entirely preclinical: - *No human trials.* There are no published human clinical trials of KPV; the entire efficacy literature is in vitro and animal (chiefly murine colitis), so human dosing, efficacy and safety are unestablished [20]. - *Fragility and no human PK.* Free KPV is a small, peptidase-labile tripeptide with no validated human pharmacokinetics, which is exactly why so much of the field's effort goes into formulations that keep it intact long enough to act [19]. - *Marketing outruns evidence.* Promotion of KPV for gut health, skin, or general anti-inflammatory use runs ahead of an evidence base that is mechanistic and preclinical, not clinical. - *Not a tanning peptide.* Although KPV derives from alpha-MSH, it should be distinguished from melanocortin agonists used for pigmentation; its defining property is anti-inflammatory action *without* pigment effect [22]. - *Citation hygiene.* PMID/DOI errors are common in secondary web sources for KPV, so identifiers should be checked at the source rather than copied from aggregators. - *Research-use status.* KPV is sold by chemical suppliers for laboratory research only and is not an approved drug or dietary supplement. No community-anecdote reports are compiled in this desk's source material for KPV, so none are presented; the cautions above are from the cited literature. ## Where it fits in recovery research KPV is the odd one out on this desk, in a useful way. Where [BPC-157](/bpc-157), [TB-500](/tb-500) and [GHK-Cu](/ghk-cu) all build or migrate tissue, KPV works the other side of repair — turning *down* the inflammatory noise that can keep a wound from closing [20]. Its evidence is the most uniformly preclinical of the four (no human trials at all), but its mechanism is among the most precisely mapped, right down to the PepT1 transporter and an MC1R-independent anti-inflammatory route [21]. It completes the desk's four-sided view of recovery: blood supply, cell movement, scaffolding, and inflammation. See the [comparison page](/compare) for the side-by-side. ![KPV tripeptide passing through a cell-membrane transporter with quieting ripples](/images/kpv.webp) --- A cross-referenced reading desk for recovery-peptide research — citations, not prescriptions, and never a product for sale.